|Description||G-TPP is a mitochondria-targeted Hsp90 inhibitor that increases cell death in HeLa and MCF7 cells, consistently inhibits cell death induced by oxidative stress and mitochondrial dysfunction induced by PINK1 mutation in mouse embryonic fibroblast cells and DA cell models such as SH-SY5Y and SN4741 cells. Additionally, G-TPP also suppresses the defective locomotive activity and DA neuron loss in Drosophila PINK1 null mutants.|
|Brife Description||G-TPP is a mitochondria-targeted Hsp90 inhibitor|
|Storage||3 years -20oC powder, 6 months-80oC in solvent.|
Alvespimycin hydrochloride is the hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds...
NVP-BEP800 is a novel, fully synthetic Hsp90β inhibitor with IC50 of 58 nM, exhibits >70-fold selectivity against Hsp90 family members Grp94 and Trap-1.
Chlorobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 60μmol/...
Novobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the interaction of both p23 and Hsp70 co-chaperones ...
VER-49009 is a pyrazole compound inhibitor of Hsp90, IC50 47 nM. It produces a cellular antiproliferative GI50 value of 685 nM when tested against a human cance...
Luminespib, also known as AUY-922 (or NVP-AUY922), is a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with po...
CCT018159 is a novel inhibitor of heat shock protein (Hsp) 90 with potential anticancer activity. CCT018159 inhibited human Hsp90beta with comparable potency to...
Hsp980 is an orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp980 binds to and inhibits the acti...
Nanoparticle albumin-bound 17-AAG
Triolimus is a composed of a micelle containing the drugs rapamycin, 17-AAG, and paclitaxel, which act synergistically to inhibit tumor growth
Pochocin A is a patent Hsp90 inhibitor. IC50 90nM.
DS-2248 is an orally active and small molecule inhibitor of Hsp90, with potential antineoplastic activity. Upon oral administration, Hsp90 inhibitor DS-2248 spe...
PF-4942847 is a novel oral Hsp90 inhibitor, which is a candidate for clinical development in TNBC by collaboratively targeting multiple signaling pathways. In a...
NMS-E973 shows a widespread antiproliferative activity with an average IC50 of 1.6 μM, and induces the degradation of client protein.
Macbecin I is an ansamycin antibiotic compound that inhibits Hsp90 by binding to the ATP-binding site.IC50 = 2μM. Exhibits antitumor and cytocidal activities (I...
Radester is a hybrid composed of radicicol's resorcinol and geldanamycin’s benzoquinone part structures and exhibits good cellular activity against MCF7 breast ...
STA-1474 is a H2O soluble prodrug of ganetespib (formerly STA-9090). STA-1474 will metabolize to Ganetespib, which is a potent Hsp90 inhibitor previously shown ...
Geldanamycin is a benzoquinone ansamycin antibiotic that binds to Hsp90 (Heat Shock Protein 90) and inhibits its function. Hsp90 client proteins play important ...
Sansalvamide A binds directly to Hsp90 and modulate Hsp90's binding with client proteins.
PU-WS13 is a cell-permeable inhibitor of Grp94 (EC50 = 220 nM).It shows selectivity for Grp94 over the related Hsps Trap-1, Hsp90α, and Hsp90β. PU-WS13 blocks t...